Ibogaine Cardiac Screening: QT Prolongation Explained

Ibogaine cardiac screening for QT prolongation is the one test almost everyone hears about before treatment and almost no one understands. Clinics say "we do an ECG," patients nod, and the conversation moves on to cost and dates. That is a missed opportunity, because the QT interval is the single number that most directly decides whether ibogaine is a reasonable risk for you, and it is not hard to understand once someone explains it in plain language.

This guide is written for the patient, not the cardiologist. It covers what the QT interval measures, why ibogaine lengthens it, what a proper pre-treatment cardiac screen includes, and how the number changes during and after a flood dose. It does not replace a physician's evaluation; it makes you a better participant in one.

Why ibogaine cardiac screening centers on QT prolongation

Every heartbeat is an electrical event. The heart's muscle cells charge up, fire, and then reset before they can fire again. That reset, called repolarization, depends on potassium flowing out of the cells through specific channels. One of the most important is the hERG channel, and laboratory work published in the early 2010s showed that ibogaine and its main metabolite, noribogaine, block it.

Block the channel, and the reset takes longer. On an ECG, a longer reset shows up as a longer QT interval. A modestly longer QT is common with many drugs and is usually harmless.

A substantially longer one raises the chance of a dangerous rhythm called torsades de pointes, which can degenerate into cardiac arrest. Published case reports of ibogaine deaths cluster around cardiac events, and QT prolongation is the mechanism most consistently implicated.

Two features make ibogaine unusual. First, the effect is dose-dependent, and flood doses used for opioid detox are large. Second, noribogaine clears from the body slowly, so the QT can stay prolonged for days after the acute experience has ended. If you are new to the compound, the overview of what is ibogaine covers the pharmacology; the rest of this article assumes that background and focuses on the heart.

What does the QT interval measure on an ECG?

A standard ECG tracing shows a small bump (the P wave), a sharp spike (the QRS complex), and a broader hump (the T wave). The QT interval runs from the start of the QRS complex to the end of the T wave. In plain terms, it is the time the ventricles take to fire and then fully reset.

The raw QT depends on heart rate: a faster heart has a shorter QT simply because everything is compressed. To compare readings fairly, clinicians use a corrected value, the QTc. Two correction formulas matter for ibogaine patients:

• Bazett's formula is the default on most ECG machines. It works well at normal heart rates but overcorrects when the heart is fast, producing an artificially long QTc.
• Fridericia's formula is more accurate at higher heart rates and is preferred by many cardiologists for drug-safety assessment.

This matters more than it sounds. Someone in early opioid withdrawal often has a fast resting heart rate, so a Bazett-corrected QTc from the machine's automatic readout may look worse than the true picture. A clinic that knows what it is doing will have a physician read the tracing and, where the heart rate is elevated, recalculate using Fridericia. Ask which formula was used; the answer tells you whether a human looked at your ECG.

Cardiology generally treats a QTc above roughly 450 milliseconds in men and 460 in women as prolonged, and a value approaching 500 milliseconds as the point where arrhythmia risk climbs sharply. Ibogaine clinics with strong protocols commonly set their own admission ceiling below the general cardiology threshold, because the drug is going to push the number up from wherever it starts.

What a proper pre-treatment cardiac screen includes

A resting ECG is necessary but not sufficient. The screen that protects you has several parts, and the ibogaine pre-screening tool on this site walks through the questions a clinic should be asking before any of it is ordered.

A 12-lead resting ECG, read by a physician. The machine's printed interpretation is a starting point, not a verdict. A doctor should confirm the QTc, note the heart rate, and look for anything else that changes the plan, such as conduction abnormalities or signs of prior heart damage.

Electrolytes. Low potassium, low magnesium, and low calcium each lengthen the QT on their own. Vomiting and diarrhea during withdrawal deplete all three. A clinic should measure them and correct them before dosing, not discover them afterward.

A complete medication review. Many common drugs prolong the QT, and the effect stacks with ibogaine. Methadone is the most important example for this population, because it is both a QT-prolonging drug and a long-acting opioid that many people are trying to leave.

Certain antipsychotics, some antidepressants, several antibiotics, and some anti-nausea medications belong on the same list. None of these are automatic disqualifiers, but every one of them needs a physician's decision about tapering, timing, or substitution, coordinated with the prescriber.

Personal and family cardiac history. Fainting episodes, palpitations, a diagnosed arrhythmia, or a relative who died suddenly at a young age all raise the possibility of an inherited long QT syndrome, which can be present even when a single resting ECG looks normal.

Further imaging when indicated. An echocardiogram looks at the heart's structure and pumping function. It is not required for everyone, but a history of heart disease, heavy stimulant use, or an abnormal ECG should trigger one. Some programs also use a stress test for older patients or those with risk factors.

A screen that stops at "we ran an ECG and it was fine" has done a fifth of the job.

How the QT changes during and after the dose

The QT does not jump at the moment of dosing. It lengthens as ibogaine is absorbed and as noribogaine accumulates, typically peaking hours into the session. The heart rate usually slows at the same time, which is expected but worth watching, since a slow rate combined with a long QT is a riskier pairing than either alone.

Because of noribogaine's slow clearance, the QT commonly stays prolonged well into the days after treatment. This is why reputable clinics keep patients on continuous cardiac monitoring during the session and for a substantial period afterward, generally described as at least 24 to 72 hours depending on the protocol and the individual's readings. Serial ECGs during this window show whether the interval is heading back toward baseline.

Several routine measures reduce risk during this period. IV access is established before dosing so that fluids and medications can be given immediately. Magnesium is often administered because it stabilizes the heart's electrical activity.

Anti-nausea strategies are chosen with the QT in mind, since some common antiemetics would make the problem worse. Electrolytes are rechecked, especially if there has been vomiting.

The window after the acute experience is where under-resourced programs fail. A patient who feels fine on day two may still have a prolonged QT, and the risk does not care how the patient feels.

Who gets screened out, and what "borderline" means

Some findings are hard stops at any responsible clinic: a prolonged QTc at baseline, a known arrhythmia, structural heart disease, a recent heart attack, or an inherited long QT syndrome. Being turned away for one of these is not a failure of the process; it is the process working.

Many patients fall into a borderline category instead. The QTc is a little high, or a QT-prolonging medication is still on board, or the potassium is low. The right response is not a coin flip.

It is a plan: correct the electrolytes, work with the prescriber on the medication, repeat the ECG after a defined interval, and make the decision on the new numbers. For people on methadone, this often means a supervised transition to a shorter-acting opioid before treatment, which takes time and must not be rushed.

If a clinic offers to treat you despite a borderline reading without any of these steps, the willingness is not a kindness.

Questions to ask a clinic about its ECG protocol

Bring these to the intake call. The answers are more informative than any marketing page.

• Who reads my ECG, and which QTc correction formula do you use?
• What QTc value would cause you to postpone or decline treatment?
• Do you measure potassium and magnesium before dosing, and do you correct them?
• How do you handle patients currently on methadone or other QT-prolonging medications?
• Is a physician on site during the session, and what monitoring is used?
• How long after dosing does continuous cardiac monitoring continue, and how many follow-up ECGs are taken?
• What emergency equipment and medications are in the treatment room, and how far is the nearest hospital?

A clinic with a real protocol will answer every one of these in specifics. Hesitation on any of them is a signal.

Ibogaine cardiac screening for QT prolongation is not a formality to pass on the way to treatment. It is the point at which a clinic decides, with evidence, whether the risk is acceptable for you specifically, and it continues through the days after the dose when the danger is quietest and least visible. Understanding what the QTc measures lets you check that the screening you are offered is the real thing.

For a broader picture of how screening, treatment, and aftercare fit together, the ibogaine treatment guide covers each stage in the same plain language. Read it before you call a clinic, and bring the questions above with you.

This article is for education and is not medical advice. Decisions about ibogaine treatment should be made with a qualified physician who has reviewed your full medical history.